tbuckley/cabot-search huggingface dataset:
EBV infection in premalignant nasopharyngeal epithelial cell model
Authors: Chi Man Tsang, Kenzo Takada, Eri Seto, Sai Wai Tsao
Journal: Cancer Research (2008)

2965  Epstein-Barr virus (EBV) is associated with the development of nasopharyngeal carcinoma (NPC). EBV genome is present in most if not all nasopharyngeal carcinoma cells. Expression of EBV genes in premalignant nasopharyngeal epithelial (NP) cells may drive their transformation into cancer cells. However, previous studies on the transformation mechanisms of EBV were mostly performed in non-nasopharyngeal cancer cell lines, that might not have the cellular context for the transformation actions of EBV, especially those involved in the early events in NPC carcinogenesis. Our lab has newly immortalized an NP cell line from primary non-malignant nasopharyngeal biopsies, named as NP460, and has been used in this study to examine the roles of EBV in NPC development.  In my study, a genetic recombinant EBV tagged with GFP and drug selection marker was successfully introduced into NP460 cells. The EBV gene expression pattern after the infection was examined by RT-PCR. EBER, EBNA1, LMP1 and LMP2A were expressed, reflecting the similar latent II expression profile of EBV infection in the NPC. By doing proliferation assay, wound healing assay, collagen assay and soft-agar assay, we did not observed enhancement in proliferation, cell mobility, invasiveness and anchorage independent growth in the EBV-infected NP460 cells. Interestingly, when the EBV infected NP460 cells were subjected to differentiation induction using serum, the LMP2A expression and exosome secretion were greatly upregulated. Our results indicate that differentiation of NP cells have strong influence on the expression of EBV latent genes. The functional significance of enhanced exosome secretion and its potential involvement in immunomodulation is under current investigation.  To conclude, we have established an EBV-infected premalignant NP cell model for understanding the pathogenesis of NPC and further elucidation of cellular factors involved in the development of NPC may provide useful target for therapeutic intervention of NPC.
P1.03-028 Wolf in Sheep's Clothing - Primary Lung Cancer Mimicking Benign Diseases
Authors: Annemie Snoeckx, Damien Desbuquoit, Amélie Dendooven, Maarten Spinhoven, Birgitta Hiddinga, Laurens Carp, Paul Van Schil, Paul Parizel, Jan Van Meerbeeck
Journal: Journal of Thoracic Oncology (2017)
Perinatal mortality associated with induction of labour versus expectant management in nulliparous women aged 35 years or over: An English national cohort study
Authors: Hannah E. Knight, David A. Cromwell, Ipek Gurol-Urganci, Katie Harron, Jan H. van der Meulen, Gordon C. S. Smith
Journal: PLoS Medicine (2017)

Background A recent randomised controlled trial (RCT) demonstrated that induction of labour at 39 weeks of gestational age has no short-term adverse effect on the mother or infant among nulliparous women aged ≥35 years. However, the trial was underpowered to address the effect of routine induction of labour on the risk of perinatal death. We aimed to determine the association between induction of labour at ≥39 weeks and the risk of perinatal mortality among nulliparous women aged ≥35 years. Methods and findings We used English Hospital Episode Statistics (HES) data collected between April 2009 and March 2014 to compare perinatal mortality between induction of labour at 39, 40, and 41 weeks of gestation and expectant management (continuation of pregnancy to either spontaneous labour, induction of labour, or caesarean section at a later gestation). Analysis was by multivariable Poisson regression with adjustment for maternal characteristics and pregnancy-related conditions. Among the cohort of 77,327 nulliparous women aged 35 to 50 years delivering a singleton infant, 33.1% had labour induced: these women tended to be older and more likely to have medical complications of pregnancy, and the infants were more likely to be small for gestational age. Induction of labour at 40 weeks (compared with expectant management) was associated with a lower risk of in-hospital perinatal death (0.08% versus 0.26%; adjusted risk ratio [adjRR] 0.33; 95% CI 0.13–0.80, P = 0.015) and meconium aspiration syndrome (0.44% versus 0.86%; adjRR 0.52; 95% CI 0.35–0.78, P = 0.002). Induction at 40 weeks was also associated with a slightly increased risk of instrumental vaginal delivery (adjRR 1.06; 95% CI 1.01–1.11, P = 0.020) and emergency caesarean section (adjRR 1.05; 95% CI 1.01–1.09, P = 0.019). The number needed to treat (NNT) analysis indicated that 562 (95% CI 366–1,210) inductions of labour at 40 weeks would be required to prevent 1 perinatal death. Limitations of the study include the reliance on observational data in which gestational age is recorded in weeks rather than days. There is also the potential for unmeasured confounders and under-recording of induction of labour or perinatal death in the dataset. Conclusions Bringing forward the routine offer of induction of labour from the current recommendation of 41–42 weeks to 40 weeks of gestation in nulliparous women aged ≥35 years may reduce overall rates of perinatal death.
Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa
Authors: Jacob Bor, Matthew P. Fox, Sydney Rosen, Atheendar Venkataramani, Frank Tanser, Deenan Pillay, Till Bärnighausen
Journal: PLoS Medicine (2017)

Background Loss to follow-up is high among HIV patients not yet receiving antiretroviral therapy (ART). Clinical trials have demonstrated the clinical efficacy of early ART; however, these trials may miss an important real-world consequence of providing ART at diagnosis: its impact on retention in care. Methods and findings We examined the effect of immediate (versus deferred) ART on retention in care using a regression discontinuity design. The analysis included all patients (N = 11,306) entering clinical HIV care with a first CD4 count between 12 August 2011 and 31 December 2012 in a public-sector HIV care and treatment program in rural South Africa. Patients were assigned to immediate versus deferred ART eligibility, as determined by a CD4 count < 350 cells/μl, per South African national guidelines. Patients referred to pre-ART care were instructed to return every 6 months for CD4 monitoring. Patients initiated on ART were instructed to return at 6 and 12 months post-initiation and annually thereafter for CD4 and viral load monitoring. We assessed retention in HIV care at 12 months, as measured by the presence of a clinic visit, lab test, or ART initiation 6 to 18 months after initial CD4 test. Differences in retention between patients presenting with CD4 counts just above versus just below the 350-cells/μl threshold were estimated using local linear regression models with a data-driven bandwidth and with the algorithm for selecting the bandwidth chosen ex ante. Among patients with CD4 counts close to the 350-cells/μl threshold, having an ART-eligible CD4 count (<350 cells/μl) was associated with higher 12-month retention than not having an ART-eligible CD4 count (50% versus 32%), an intention-to-treat risk difference of 18 percentage points (95% CI 11 to 23; p < 0.001). The decision to start ART was determined by CD4 count for one in four patients (25%) presenting close to the eligibility threshold (95% CI 20% to 31%; p < 0.001). In this subpopulation, having an ART-eligible CD4 count was associated with higher 12-month retention than not having an ART-eligible CD4 count (91% versus 21%), a complier causal risk difference of 70 percentage points (95% CI 42 to 98; p < 0.001). The major limitations of the study are the potential for limited generalizability, the potential for outcome misclassification, and the absence of data on longer-term health outcomes. Conclusions Patients who were eligible for immediate ART had dramatically higher retention in HIV care than patients who just missed the CD4-count eligibility cutoff. The clinical and population health benefits of offering immediate ART regardless of CD4 count may be larger than suggested by clinical trials.
It's not just about the future: The present payoffs to behaviour vary in degree and kind between the rich and the poor
Authors: Rebecca Sear, Susan B. Schaffnit
Journal: Behavioral and Brain Sciences (2017)

Abstract Pepper &amp; Nettle offer a nuanced and humane view on poverty that should be required reading for policy makers, particularly those interested in “behaviour change” policy. We suggest, however, that the emphasis on “future-discounting” in this paper downplays the importance of differences in the payoffs to behaviours in the present and how these payoffs may be realised in different currencies.
P2.03a-018 A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
Authors: James Godwin, Jessica Bauman, Samuel Litwin, Ranee Mehra, Anthony Olszanski, Hossein Borghaei
Journal: Journal of Thoracic Oncology (2017)
A novel prognostic score based on inflammation and nutrition in colorectal cancer patients
Authors: S. Fujino, N. Miyoshi, Y. Takahashi, M. Yasui, M. Ohue, K. Saso, T. Hata, C. Matsuda, T. Mizushima, Y. Doki, M. Mori
Journal: Annals of Oncology (2017)
P2.06-044 Frequency of Mutations and Related Factors in Lung Adenocarcinoma Cases in Turkey
Authors: Senay Yilmaz, Mehmet Karadag, Nilgun Demirci, Derya Kızılgöz, Pınar Akın Kabalak, Muzaffer Metintas, Guntulu Ak, Ugur Yılmaz, Berna Komurcuoglu, Ozge Guclu, Akın Ozturk, Tugce Ozdemirel, Tuba Inal Cengiz, Berna Ozyurek, Yurdanur Erdogan, Sedat Altin, Pinar Celik, Gulsah Gunluoglu, Gaye Ulubay, Adil Zamani, Murat Kavas, Dursun Tatar, Selma Metintas
Journal: Journal of Thoracic Oncology (2017)
Humanized recombinant endostatin combined with vinorelbine plus cisplatin followed by maintenance therapy with humanized recombinant endostatin in advanced non-small cell lung cancer: A multicentre, double-blind, randomised phase 3 trial
Authors: Y-K Shi, L. Zhang, S. Zhang, M. Shi, S. Qin, C. Wu, Z. Zhuang, G. Mao, D. Hua, X. Zhou, Y. Qu, Y. Wang, X. Shi, C. Hu, W. Li, M. Ouyang, L. Chen, Y. Sun, G. Wu, Y. Sun
Journal: Annals of Oncology (2017)
The Evidence Basis for the American College of Rheumatology Practice Guidelines
Authors: Alí Duarte-García, Richard Zamore, John B. Wong
Journal: JAMA Internal Medicine (2017)

changes in Medicaid fees-Illinois, New Jersey, Pennsylvania, and Texas-all experienced substantial increases in appointment availability when Medicaid fees increased; New Jersey and Texas also experienced substantial decreases in appointment availability when Medicaid fees decreased.Overall, a $10 change in Medicaid fees was estimated to be associated with a 1.7 percentage point (95% CI, 1.2 to 2.1; P < .001)change in appointment availability for new Medicaid patients (Figure).There was no evidence that the response to increasing fees differed from the response to decreasing fees.In contrast, 11 071 calls made by privately insured simulated patients in the audit study were analyzed.No association between Medicaid fees and appointment availability was detected (95% CI, -0.4 to 1.1; P = .28).This finding suggests that changes in physician access in Medicaid were driven by Medicaid fees rather than potentially confounding changes to primary care.Discussion | The association between Medicaid fees and primary care appointment availability for new Medicaid patients is robust and not dependent on whether fees increase or decrease.Historically, reductions in Medicaid funding have led to states lowering their Medicaid fees. 5These findings indicate that reductions in Medicaid funding would affect the breadth of primary care physician participation in Medicaid and may compromise access to primary care for new Medicaid patients.
Abstract 20454: Electronic Cigarette Aerosols and Constituents Induce Bradycardia and Prolonged QT in Mice -- Does E-Cigarette Use Increase Cardiovascular Disease Risk?
Authors: Alex P Carll, Renata Salatini, Claudia Arab, Daniel G Holbrook, Aruni Bhatnagar, Daniel J Conklin
Journal: Circulation (2017)

Introduction: Electronic nicotine delivery systems (ENDS, including E-cigarettes) use is increasing rapidly, especially among youth who perceive ENDS as generally safer than smoking. The cardiovasc...
Renal artery stenosis
Authors: D. Kerr, R. Tattersall
Journal: BMJ (1991)

superior mesenteric angiography in acute ischaemia remains controversial.Appreciable mesenteric embolus or stenosis of the superior mesenteric arterv may occasionally be recognised, but atten- tion should be drawn to accumulating evidence that catheterisation or manipulation of a diseased aorta may itself predispose to cholesterol emboli. 1 4 These commonly affect kidneys, pancreas, and peripheral circulation but may also affect the gastrointestinal tract.'In addition to the release of oxygen derived free radicals by the gut mucosa, there is evidence that trapping and activating white cells in the microcirculation contributes to the cycle of stasis and endothelial and mucosal damage that occurs in intestinal ischaemia.cWhen reperfusion is considered, prostacyclin analogues, which vasodilate, reduce white cell and platelet aggregability, and confer a "cytoprotective" effect on ischaemic tissues,, should be added to the list of potentially useful protective pharmacological adjuncts.We are currently evaluating the role of such compounds in preventing reperfusion injury.
Obstructive Sleep Apnea and Cardiovascular Disease. REM Sleep Matters!
Authors: Babak Mokhlesi, Andrew W. Varga
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

on group-level data and estimates of MCID are applied with caution to individual patients when making treatment or funding decisions, and to ensure that trial-derived metrics do not become a barrier to accessing emerging therapies for uncommon life-threatening diseases with few management options.
Sir Graham Wilson and Sir Ashley MilesM.T. Parker, Editor (Seventh Edition.), Principles of Bacteriology, Virology and Immunity Vol. 3, Edward Arnold, Cambridge (1984), p. 610.G.R. Smith, Editor, Bacterial Diseases Vol. 4 (1984), p. 584.F. Brown and Sir Graham Wilson, Editors, Virology (1984) £72.50.
Authors: J COLLEE
Journal: Journal of Infection (1985)
P2.03a-042 Comorbidity as a Prognostic Factor in Elderly Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Danica Sazdanic-Velikic, Aleksandar Tepavac, Nensi Lalic, Ivana Stojkovic, Nevena Secen
Journal: Journal of Thoracic Oncology (2017)
P3.01-019 Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer
Authors: Roya Navab, Melania Pintilie, Venkata Satya Kumar Manem, Tomas Tokar, Benjamin Haibe-Kains, Igor Jurisica, Ming Tsao
Journal: Journal of Thoracic Oncology (2017)
Association of Clinician Denial of Patient Requests With Patient Satisfaction
Authors: Anthony Jerant, Joshua J. Fenton, Richard L. Kravitz, Daniel J. Tancredi, Elizabeth Magnan, Klea D. Bertakis, Peter Franks
Journal: JAMA Internal Medicine (2017)

Prior studies suggesting clinician fulfillment or denial of requests affects patient satisfaction included limited adjustment for patient confounders. The studies also did not examine distinct request types, yet patient expectations and clinician fulfillment or denial might vary among request types.To examine how patient satisfaction with the clinician is associated with clinician denial of distinct types of patient requests, adjusting for patient characteristics.Cross-sectional observational study of 1319 outpatient visits to family physicians (n = 56) by 1141 adults at one Northern California academic health center.We used 6 Consumer Assessment of Healthcare Providers and Systems Clinician and Group Adult Visit Survey items to measure patient satisfaction with the visit physician. Standardized items were averaged to form the satisfaction score (Cronbach α = 0.80), which was then percentile-transformed. Seven separate linear mixed-effects models examined the adjusted mean differences in patient satisfaction percentile associated with denial of each of the following requests (if present)-referral, pain medication, antibiotic, other new medication, laboratory test, radiology test, or other test-compared with fulfillment of the respective requests. The models adjusted for patient sociodemographics, weight, health status, personality, worry over health, prior visit with clinician, and the other 6 request categories and their dispositions.The mean (SD) age of the 1141 patients was 45.6 (16.1) years, and 902 (68.4%) were female. Among 1319 visits, 897 (68.0%) included at least 1 request; 1441 (85.2%) were fulfilled. Requests by category were referral, 294 (21.1%); pain medication, 271 (20.5%); antibiotic, 107 (8.1%); other new medication, 271 (20.5%); laboratory test, 448 (34.0%); radiology test, 153 (11.6%); and other tests, 147 (11.1%). Compared with fulfillment of the respective request type, clinician denials of requests for referral, pain medication, other new medication, and laboratory test were associated with worse satisfaction (adjusted mean percentile differences, -19.75 [95% CI, -30.75 to -8.74], -10.72 [95% CI, -19.66 to -1.78], -20.36 [95% CI, -29.54 to -11.18], and -9.19 [95% CI, -17.50 to -0.87]), respectively.Clinician denial of some types of requests was associated with worse patient satisfaction with the clinician, but not for others, when compared with fulfillment of the requests. In an era of patient satisfaction-driven compensation, the findings suggest the need to train clinicians to deal effectively with requests, potentially enhancing patient and clinician experiences.
Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone
Authors: Hernan Roca, Jacqueline D. Jones, Marta C. Purica, Savannah Weidner, Amy J. Koh, Robert Kuo, John E. Wilkinson, Yugang Wang, Stephanie Daignault-Newton, Kenneth J. Pienta, Todd M. Morgan, Evan T. Keller, Jacques E. Nör, Lonnie D. Shea, Laurie K. McCauley
Journal: Journal of Clinical Investigation (2017)

During tumor progression, immune system phagocytes continually clear apoptotic cancer cells in a process known as efferocytosis. However, the impact of efferocytosis in metastatic tumor growth is unknown. In this study, we observed that macrophage-driven efferocytosis of prostate cancer cells in vitro induced the expression of proinflammatory cytokines such as CXCL5 by activating Stat3 and NF-κB(p65) signaling. Administration of a dimerizer ligand (AP20187) triggered apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis-inducible prostate cancer cells were either coimplanted with vertebral bodies, or inoculated in the tibiae of immunocompetent mice. Induction of 2 pulses of apoptosis correlated with increased infiltration of inflammatory cells and accelerated tumor growth in the bone. Apoptosis-induced tumors displayed elevated expression of the proinflammatory cytokine CXCL5. Likewise, CXCL5-deficient mice had reduced tumor progression. Peripheral blood monocytes isolated from patients with bone metastasis of prostate cancer were more efferocytic compared with normal controls, and CXCL5 serum levels were higher in metastatic prostate cancer patients relative to patients with localized prostate cancer or controls. Altogether, these findings suggest that the myeloid phagocytic clearance of apoptotic cancer cells accelerates CXCL5-mediated inflammation and tumor growth in bone, pointing to CXCL5 as a potential target for cancer therapeutics.
Self-reported adverse food reactions and anaphylaxis in the SchoolNuts study: A population-based study of adolescents
Authors: Vicki L. McWilliam, Jennifer J. Koplin, Michael J. Field, Mari Sasaki, Shyamali C. Dharmage, Mimi L.K. Tang, Susan M. Sawyer, Rachel L. Peters, Katrina J. Allen
Journal: Journal of Allergy and Clinical Immunology (2017)
Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post‐capillary pulmonary hypertension
Authors: Stefano Ghio, Gabriele Crimi, Pier Luigi Temporelli, Egidio Traversi, Maria Teresa La Rovere, Antonia Cannito, Dario Vizza, Laura Scelsi, Claudia Raineri, Marco Guazzi, Luigi Oltrona Visconti
Journal: European Journal of Heart Failure (2017)
Knowledge and attitudes of productive age women about “SADARI” (breast self-assessment) in early detection of breast cancer in Tihingan village, Klungkung, Bali
Authors: A.B.S. Satyarsa, L.P. Diah Virayanti, S.A. Arta Suryantari, P.A.T. Adiputra
Journal: Annals of Oncology (2017)
Health providers’ perspectives on medical marijuana use.
Authors: Diana Martins-Welch, Christian Nouryan, Myriam Kline, Sony Modayil
Journal: Journal of Clinical Oncology (2017)

235 Background: According to the CDC, 117 million Americans have one or more chronic health conditions and 31% have used two or more prescription drugs in the past month. Approximately 40% of adults in the United States are using some form of Complementary and Alternative Medicine. Medical marijuana is one such medicine, and to date 29 states have legalized medical marijuana. Methods: A multicenter, anonymous, on-line survey of health care providers was distributed via e-mail within a large health system in the NY Metropolitan area. The survey was distributed in April and May of 2017. The specific aim was to collect information about health care providers’ perspectives on the use of MM in general and for specific medical conditions. Results: The sample (n = 137) consisted of 4% RNs, 10% NPs, 10% fellows, 21% resident physicians, and 52% attending physicians. Average experience was 13 years (range: 0-43), half (53%) were under 40 years old and just over half (56%) were female. Most practitioners recognized a benefit of MM for the treatment of cancer-associated symptoms, few were concerned with side effects and 5% of responders answered that MM was not appropriate at any stage of illness. Responders were “most likely to recommend or refer MM if other therapies were not effective” for cancer (83%), chronic pain (68%), spinal cord injury with spasticity (50%), MS (46%), epilepsy (42%), neuropathy (42%) and Parkinson’s disease (41%). Most providers (77%) believed that MM has the potential to reduce overall opioid use, this was found to be statistically more common in younger providers. The most common conditions that providers reported their patients were requesting MM for were cancer (37%), chronic pain (26%) and neuropathy (10%). The most common concerns about MM use were side effects (16%), addiction (13%), legal consequences (11%), cost (7%) and that other providers would judge MM use (7%). Conclusions: Our survey shows that providers are overwhelmingly in support of MM use in patients with chronic illness, particularly in cancer patients. However providers describe significant and practical concerns about MM utilization. Given the rate at which MM is being legalized throughout the country, it is imperative that there be increased focus on education and clinical studies on MM.